Bausch Health Companies Inc.

GRI Bio, Inc.

Supernus Pharmaceuticals, Inc.

Eikon Therapeutics, Inc.

Candel Therapeutics, Inc.

Compass Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Cartesian Therapeutics, Inc.

Annovis Bio, Inc.

Dilution score: 20/100 (LOW), 999.0 months cash

13F fund flow: accumulation, 27 institutional managers

AQR Capital

Brevan Howard

Tudor

Arrowstreet

Paulson & Co

Marshall Wace

Franklin Templeton

DE Shaw

BlackRock

197 PubMed publications found for Bausch Health Companies .

Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.

Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study.

The American Society of Clinical Psychopharmacology task force consensus statement on the deprescribing of stimulant medications in adults with ADHD(✰).

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.

Short interest: 2.82% of float, squeeze risk: LOW

SW convergence: 36/100 (Bearish Convergence), 0 bullish / 2 bearish signals

<article class="bts-verified-summary" data-ticker="BHC">
<p>Bausch Health Companies Inc. (BHC) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>BHC has 10 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0000885590 (2026-06-17) <a href="https://efts.sec.gov/LATEST/search-index?q=%22BHC%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-05-18&amp;enddt=2026-06-17" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR — 0000885590

Bausch Health Companies Inc. (BHC) — BioTechSigns Verified Summary

Bausch Health Companies Inc. (BHC) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

BHC has 10 Form 4 insider filings recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0000885590. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://efts.sec.gov/LATEST/search-index?q=%22BHC%22&forms=4&dateRange=custom&startdt=2026-05-18&enddt=2026-06-17